韋瑋,王力,梁麗,王逾珍,海麗娜,楊秀偉*
(1.北京大學(xué) 藥學(xué)院 天然藥物學(xué)系,天然藥物及仿生藥物國家重點實驗室,北京 100191;2.長治醫(yī)學(xué)院,山西 長治 046000;3.北京振東光明藥物研究院有限公司,北京 100120)
中藥藥對“都梁丸”化學(xué)成分的研究△
韋瑋1,王力2a,梁麗2a,王逾珍2a,海麗娜3,楊秀偉1*
(1.北京大學(xué) 藥學(xué)院 天然藥物學(xué)系,天然藥物及仿生藥物國家重點實驗室,北京 100191;2.長治醫(yī)學(xué)院,山西 長治 046000;3.北京振東光明藥物研究院有限公司,北京 100120)
目的:研究中藥藥對“都梁丸”的化學(xué)成分。方法:采用硅膠、高效液相等柱色譜方法進行分離純化,通過質(zhì)譜、核磁共振等譜學(xué)數(shù)據(jù)鑒定化合物結(jié)構(gòu)。結(jié)果:從“都梁丸”環(huán)己烷、乙酸乙酯、正丁醇萃取部位中共鑒定了41個化合物,分別為5-羥甲基糠醛(1),香草醛(2),阿魏酸(3),松柏醛(4),花椒毒素(5),佛手酚(6),鐮葉芹二醇(7),洋川芎內(nèi)酯 H(8),洋川芎內(nèi)酯I(9),洋川芎內(nèi)酯D(10),4-羥基-3-丁基苯酞(11),洋川芎內(nèi)酯A(12),Z-藁本內(nèi)酯(13),3-丁烯基苯酞(14),新蛇床內(nèi)酯(15),歐當(dāng)歸內(nèi)酯A(16),β-谷甾醇(17),異茴芹內(nèi)酯(18),鄰苯二甲酸正丁酯(19),鄰苯二甲酸異丁酯(20),川芎二內(nèi)酯R1(21),白術(shù)內(nèi)酰胺(22),香柑內(nèi)酯(23),補骨脂素(24),異氧化前胡內(nèi)酯(25),珊瑚菜內(nèi)酯(26),獨活屬醇(27),牧草栓翅芹酮(28),異白當(dāng)歸腦(29),歐前胡素(30),異歐前胡素(31),別異歐前胡素(32),水合氧化前胡內(nèi)酯 (33),白當(dāng)歸素(34),印枳苷(35),(2′S,3′R)-3′-羥基印枳苷(36),仲-O-β-D-吡喃葡萄糖基白當(dāng)歸素(37),叔-O-β-D-吡喃葡萄糖基白當(dāng)歸素(38),(2′R,3′S)-3′-羥基紫花前胡苷(39),花椒毒酚-8-O-β-D-吡喃葡糖苷(40),腺苷(41)。結(jié)論:香豆素以及香豆素類成分應(yīng)來源于復(fù)方中的白芷;藁本內(nèi)酯類化合物應(yīng)來源于復(fù)方中的川芎。
都梁丸;藥對;白芷;川芎;化學(xué)成分
單味中藥是組成方劑的核心,藥有個性之特長,方有合群之妙用。單味中藥配伍成復(fù)方是中醫(yī)用藥的主要形式,亦是中醫(yī)治法治則在組方用藥上的具體應(yīng)用,顯示了傳統(tǒng)醫(yī)藥防病治病的特色。因此,中藥物質(zhì)基礎(chǔ)的研究,中藥材、飲片應(yīng)突出全成分分析和穩(wěn)定性物質(zhì)基礎(chǔ)研究,中藥復(fù)方應(yīng)突出藥效物質(zhì)基礎(chǔ)研究[1]。在系列研究中,我們報道了“黃連解毒湯”[2-4]、“通脈方”[5-9]、“左金方”和“反左金方”[10-13]、“吳茱萸湯(精制吳茱萸膠囊)”[14-16]等物質(zhì)基礎(chǔ)的研究;“都梁丸”是由白芷和川芎以4∶1質(zhì)量配比組成的蜜丸劑,已被《中華人民共和國藥典》2015版收載[17]。方中以白芷為君藥,辛溫發(fā)散、芳香走竄,善入頭部祛風(fēng)散寒、通竅止痛;輔以辛散之川芎活血行氣散風(fēng),使風(fēng)除寒散、氣血和調(diào)、祛風(fēng)散寒、活血止痛。二味藥合用,共奏祛風(fēng)散寒、活血通絡(luò)之功。本方治療風(fēng)寒之邪上犯頭部、清陽之氣受阻、氣血凝滯引起的頭痛。以傳統(tǒng)蜜丸為基礎(chǔ)的“都梁滴丸”現(xiàn)代中藥已開發(fā)上市?,F(xiàn)代藥理學(xué)研究證明“都梁丸”具有顯著的鎮(zhèn)痛作用,可能與影響痛覺調(diào)節(jié)的神經(jīng)遞質(zhì)5-羥色胺(5-HT)和5-羥吲哚乙酸(5-HIAA)等的含量有關(guān)[18-19];與抑制外周組織c-fos 基因的表達有關(guān)[20]。本文報道“都梁丸”物質(zhì)基礎(chǔ)研究。
1.1 儀器
Bruker AV III 400型核磁共振波譜儀(Bruker BioSpin AG Facilities,F(xiàn)?llanden,Switzerland),四甲基硅烷為內(nèi)標(biāo);Finnigan TRACE 2000 GC-MS質(zhì)譜儀(EI-MS;Thermo Finnigan,San Jose,CA,USA);MDS SCIEX API QSTAR型質(zhì)譜儀(ESI-TOF-MS;Applied Biosystems/MDS Sciex.,F(xiàn)oster City,CA,USA);LC 3000半制備型高效液相色譜(SP-HPLC)儀系統(tǒng)(北京創(chuàng)新通恒科技有限公司),配置P3050二元泵,CXTH-3000色譜工作站;中壓液相色譜柱(46 cm×2.6 cm,北京元寶山色譜科技有限公司);柱色譜硅膠(200~300目,青島海洋化工廠);Sephadex LH-20為Pharmacia公司產(chǎn)品;MCI-gel CHP 20(75~150 μ)為日本三菱化學(xué)產(chǎn)品;GF254薄層色譜(TLC)硅膠板分別為青島海洋化工廠和Merck公司(Darmstadt,Germany)產(chǎn)品。分析純乙醇、甲醇、乙酸乙酯、三氯甲烷、丙酮、環(huán)己烷等為北京化工廠產(chǎn)品。
1.2 材料
杭白芷藥材于2012年8月采自杭白芷道地產(chǎn)地浙江省磐安縣深澤鄉(xiāng)仰頭村,為傘形科植物Angelicadahuricacv.Hangbaizhi的干燥根;川芎藥材于2015年5月采自四川省彭州市敖平鎮(zhèn)興全村,為傘形科藁本屬植物L(fēng)igusticumchuanxiongHort.的干燥根莖。杭白芷(HBZ201208)和川芎(20150520CXR)藥材憑證標(biāo)本存放在北京大學(xué)天然藥物及仿生藥物國家重點實驗室,均經(jīng)本文作者之一楊秀偉教授鑒定為《中華人民共和國藥典》2015版規(guī)定的正品。
都梁丸藥材粉末(10 kg,其中杭白芷8 kg,川芎2 kg)用70%乙醇水溶液回流提取,料液比為1∶3,共提取8次,合并提取液,過濾后減壓回收有機溶劑至無乙醇味,加適量水,然后依次采用石油醚、乙酸乙酯、正丁醇萃取,萃取液分別旋干得到石油醚萃取部位(120 g)、乙酸乙酯萃取部位(181 g)、正丁醇萃取部位(207 g)。
石油醚萃取部位采用硅膠柱進行分離,以石油醚-乙酸乙酯(50∶11∶1)為洗脫體系進行梯度洗脫,經(jīng)TLC檢識,合并相同的流分,得到12個流分(Fr.1~Fr.12)。Fr.10(12 g)采用硅膠柱(環(huán)己烷∶乙酸乙酯=9∶1)進行分離得到4個流分(Fr.10-1~Fr.10-4)。Fr.10-4(1 g)經(jīng)HPLC制備(甲醇∶水=45∶55)分離得到7個流分(Fr.10-4-1~Fr.10-4-7)。其中Fr.10-4-3為水合氧化前胡內(nèi)酯(33,tR=30.9 min,5 mg),F(xiàn)r.10-4-4(300 mg)經(jīng)HPLC制備(乙腈∶水=15∶85)分離得到獨活屬醇(27,tR=62.1 min,25 mg)。Fr.10-4-6為洋川芎內(nèi)酯I (9,tR=49.1 min,15 mg),F(xiàn)r.10-4-7為白當(dāng)歸素(34,tR=55.1 min,200 mg)。Fr.3(2 g)經(jīng)HPLC制備(乙腈∶水=60∶40)分離得到3-丁烯基苯酞(14,tR=50.5 min,300 mg)。Fr.4 (1.5 g)采用硅膠柱(環(huán)己烷∶乙酸乙酯=9∶1)進行分離得到5個流分(Fr.4-1~Fr.4-5)。Fr.4-2(100 mg)經(jīng)過HPLC(乙腈∶水=60∶40)制備分離得到新蛇床內(nèi)酯(15,tR=31.4 min,33 mg)。Fr.4-3(195 mg)采用硅膠柱色譜(乙酸乙酯∶三氯甲烷=1∶99)進行分離得到4個流分(Fr.4-3-1~Fr.4-3-4)。其中Fr.4-3-3 (88 mg)采用硅膠柱色譜(環(huán)己烷∶乙酸乙酯=9∶1)進行分離得到2個流分(Fr.4-3-3-1~Fr.4-3-3-2)。Fr.4-3-3-2(45 mg)經(jīng)HPLC(乙腈∶水=55∶45)制備分離得到洋川芎內(nèi)酯A(12,tR=41.8 min,11 mg)。Fr.7(5 g)經(jīng)HPLC制備(甲醇∶水=70∶30)分離得到7個流分(Fr.7-1~Fr.7-7)。Fr.7-5(3 g)采用硅膠柱色譜(環(huán)己烷∶乙酸乙酯=9∶1)進行分離得到4個流分(Fr.7-5-1~Fr.7-5-4)。Fr.7-5-2(2 g)經(jīng)HPLC(乙腈∶水=45∶55)制備分離得到異歐前胡素(31,tR=25.1 min,1.0 g)。Fr.7-2(200 mg)經(jīng)HPLC(甲醇∶水=55∶45)制備分離得到4-羥基-3-丁基苯酞(11,tR=21.6 min,5 mg)。Fr.7-4(22 mg)經(jīng)HPLC(甲醇∶水=60∶40)制備分離得到補骨脂素(24,tR=34.5 min,4 mg)。Fr.8(1.5 g)經(jīng)HPLC(乙腈∶水=60∶40)制備分離得到4個流分(Fr.8-1~Fr.8-4)。Fr.8-3(550 mg)經(jīng)HPLC(乙腈∶水=45∶55)制備分離得到4個流分(Fr.8-3-1~Fr.8-3-4),歐前胡素(30,tR=81.7 min,330 mg),珊瑚菜內(nèi)酯(26,tR=102.7 min,22 mg)。
乙酸乙酯萃取部位用硅膠柱色譜分離,以石油醚-乙酸乙酯(100∶00∶1)為洗脫體系進行梯度洗脫,經(jīng)TLC檢識,合并相同的流分,得到10個流分(Fr.1~Fr.10)。Fr.1 (1 g) 經(jīng)硅膠柱色譜(環(huán)己烷∶丙酮=10∶1)等度洗脫,分別得到5-羥甲基糠醛(1,5 mg)、香草醛(2,7 mg)和松柏醛 (4,3 mg)。Fr.2(3 g)經(jīng)硅膠柱色譜(三氯甲烷∶甲醇=100∶1→10∶1)梯度洗脫,TLC檢識后合并得到3個流分(Fr.2-1~3),F(xiàn)r.2-1(1.5 g)流分采用中壓制備得到11個流分(Fr.2-1-1~11)。Fr.2-1-6(200 mg)經(jīng)HPLC制備純化得到花椒毒素(5,tR=56 min,5 mg)。Fr.2-1-7(300 mg)經(jīng)硅膠柱色譜,以環(huán)己烷-丙酮(30∶1)進行分離得到異茴芹內(nèi)酯(18,tR=212 min,8 mg)。Fr.2-1-9(700 mg)經(jīng)硅膠柱色譜(環(huán)己烷∶丙酮=49∶1)得到4個流分(Fr.2-1-9-1~4)。Fr.2-1-9-4(100 mg)經(jīng)HPLC(乙腈∶水=50∶50)制備分離得到牧草栓翅芹酮(28,tR=26 min,7 mg)。Fr.2-1-10(200 mg)經(jīng)HPLC(甲醇∶水=45∶55)制備分離得到香柑內(nèi)酯(23,tR=167 min,5 mg)。Fr.2-1-11(450 mg)經(jīng)硅膠柱色譜(環(huán)己烷∶丙酮=30∶1)得到8個流分(Fr.2-1-11-1~8)。Fr.2-1-11-5(55 mg)經(jīng)制備HPLC(甲醇∶水=60∶40)分離得到異白當(dāng)歸腦(29,tR=51 min,5 mg)。Fr.3 (1.6 g)經(jīng)硅膠柱色譜(石油醚∶丙酮=30∶1)等度洗脫得到佛手酚(6,3 mg)、鐮葉芹二醇(7,1 g)、洋川芎內(nèi)酯D(10,15 mg)。Fr.4(4 g)經(jīng)硅膠柱色譜(石油醚∶乙酸乙酯=10∶1)等度洗脫得到Z-藁本內(nèi)酯(13,400 mg)、3-丁烯基苯酞(14,100 mg)、歐當(dāng)歸內(nèi)酯A(16,20 mg)、β-谷甾醇(17,1 g)。Fr.5(600 mg)經(jīng)HPLC(乙腈∶水=70∶30,檢測波長:254 nm,流速:8 mL·min-1,進樣0.2 mL)制備,得到川芎二內(nèi)酯 R1(21,tR=3.1 min,5 mg)、白術(shù)內(nèi)酰胺(22,tR=5.0 min,6 mg)、鄰苯二甲酸正丁酯(19,tR=43.1 min,23 mg)、鄰苯二甲酸異丁酯(20,tR=45.2 min,13 mg)。Fr.6 (1 g)經(jīng)硅膠柱色譜(環(huán)己烷∶乙酸乙酯=10∶1)等度洗脫得到別異歐前胡素(32,11 mg)和水合氧化前胡內(nèi)酯(33,33 mg)。
正丁醇萃取部位用硅膠柱進行分段,以三氯甲烷-甲醇(20∶1→1∶1)為洗脫體系進行梯度洗脫,經(jīng)TLC分析后合并相似組份,共得到4個流分(Fr.1-4)。Fr.4(100 g)經(jīng)制備HPLC以乙腈水為洗脫體系(10∶90→100∶0)分段得到10個流分(Fr.4.5-1~10)。將以上流分Fr.4.5-1~10經(jīng)過TLC檢視,選擇流分進行分離。Fr.4.5-1(2 g)經(jīng)HPLC(乙腈∶水=10∶90,波長:254 nm,流速:8 mL·min-1,進樣0.2 mL)制備分段得到3個流分(Fr.4.5-1-1~3),F(xiàn)r.4.5-1-3(250 mg)經(jīng)HPLC(乙腈∶水=15∶85,波長:254 nm,流速:5 mL·min-1,進樣0.5 mL)制備分離,進一步純化得到腺苷(41,tR=13.1 min,55 mg)。Fr.4.5-2(13.5 g)經(jīng)硅膠柱(三氯甲烷∶甲醇=95∶580∶20)進行分段得到4個流分(Fr.4.5-2-1~4)。Fr.4.5-2-3(7 g)經(jīng)HPLC(乙腈∶水=20∶80,波長:254 nm,流速:15 mL·min-1,進樣1 mL)制備分段得到7個流分(Fr.4.5-2-3-1~7)。Fr.4.5-2-4(950 mg)經(jīng)HPLC(乙腈∶水=20∶80,波長:254 nm,流速:15 mL·min-1,進樣1 mL)制備分段得到4個流分(Fr.4.5-2-4-1~4)。其中,F(xiàn)r.4.5-2-4-3為印枳苷(35,tR=59.3 min,15 mg)。Fr.4.5-3(1.5 g)經(jīng)HPLC(甲醇∶酸水=25∶75,波長:254 nm,流速:8 mL·min-1,進樣0.1 mL)制備分段得到4個流分(Fr.4.5-3-1~4)。其中Fr.4.5-3-3(400 mg)經(jīng)HPLC(乙腈∶水=12∶88,波長:320 nm,流速:8 mL·min-1,進樣0.2 mL)純化得到洋川芎內(nèi)酯H (8,tR=79.3 min,8 mg)。Fr.4.5-4(900 mg)經(jīng)HPLC (甲醇∶水=30∶70) 制備分離得到2個流分(Fr4.5-4-1~2)。Fr.4.5-4-1與Fr4.5-4.2兩個流分均經(jīng)HPLC (乙腈∶水=15∶85,波長:280 nm,流速:8 mL·min-1,進樣0.5 mL),制備純化,得到(2′R,3′S)-3′-羥基紫花前胡苷(39,tR=53.9 min,30 mg)、花椒毒酚-8-O-β-D-吡喃葡萄糖苷(40,tR=55.1 min,11 mg)。Fr.4.5-5與Fr.4.5-6兩個流分合并為Fr.4.5-(5.6)(10 g),此流分經(jīng)硅膠柱色譜(三氯甲烷∶甲醇=95∶580∶20)進行分段得到6個流分[Fr.4.5-(5.6)-1~6],其中,F(xiàn)r.4.5-(5.6)-5(300 mg)經(jīng)HPLC(乙腈∶水=30∶70,波長:320 nm,流速:8 mL·min-1,進樣0.2 mL)制備分段,得到5個流分[Fr.4.5-(5.6)-5-1~5]。Fr.4.5-(5.6)-6 再經(jīng)HPLC(乙腈∶水=15∶85,波長:254 nm,流速:15 mL·min-1,進樣0.5 mL)制備分段,得到5個流分[Fr.4.5-(5.6)-6-1~5]。Fr.4.5-7(600 mg)經(jīng)HPLC (甲醇∶水=45∶55,波長:254 nm,流速:10 mL·min-1,進樣0.4 mL)制備分段,得到異氧化前胡內(nèi)酯(25,tR=57.3 min,27 mg)、仲-O-β-D-吡喃葡萄糖基白當(dāng)歸素(37,tR=61.4 min,7 mg)、叔-O-β-D-吡喃葡萄糖基白當(dāng)歸素(38,tR=64.1 min,5 mg)。Fr.4.5-7-1(100 mg)經(jīng)HPLC(乙腈∶水=17∶83,波長:254 nm,流速:8 mL·min-1,進樣0.2 mL)純化,得到阿魏酸(3,tR=9.3 min,50 mg)和(2′S,3′R)-3′-羥基印枳苷(36,tR=15 min,5 mg)。
化合物1:黃色油狀物;EI-MSm/z126 [M]+;1H-NMR (400 MHz,DMSO-d6)δ:9.50 (1H,s,CHO),7.47 (1H,d,J=3.4 Hz,H-3),6.59 (1H,d,J=3.4 Hz,H-4),4.50 (2H,s,CH2OH);13C-NMR (100 MHz,DMSO-d6)δ:178.0 (CHO),162.2 (C-5),151.8 (C-2),124.5 (C-3),109.9 (C-4),56.0 (CH2OH)。NMR數(shù)據(jù)與文獻報道一致[21],故鑒定化合物1為5-羥甲基糠醛(5-hydroxymethylfurfural)。
化合物2:白色固體(甲醇);mp 80 ℃;EI-MSm/z152 [M]+;1H-NMR (CDCl3,400 MHz)δ:9.83 (1H,s,CHO),7.44 (1H,d,J=1.8 Hz,H-2),7.42 (1H,dd,J=8.5,1.8 Hz,H-2),7.05 (1H,d,J=8.5 Hz,H-5),6.16 (1H,s,OH),3.97 (3H,s,OCH3)。NMR數(shù)據(jù)與文獻報道一致[22],故鑒定化合物2為香草醛(vanillin)。
化合物3:無色油狀物;EI-MSm/z194 [M]+;1H-NMR (400 MHz,DMSO-d6)δ:7.49 (1H,d,J=15.9 Hz,H-7),7.27 (1H,d,J=1.6 Hz,H-2),7.07 (1H,dd,J=8.1,1.6 Hz,H-6),6.79 (1H,d,J=8.1 Hz,H-5),6.37 (1H,d,J=15.9 Hz,H-8),3.81 (3H,s,3-OCH3);13C-NMR (100 MHz,DMSO-d6)δ:168.1 (C-9),149.1 (C-3),148.0 (C-4),144.4 (C-7),125.9 (C-1),122.8 (C-8),115.9 (C-6),115.6 (C-5),112.2 (C-2),55.7 (3-OCH3)。NMR數(shù)據(jù)與文獻報道一致[23],故鑒定化合物3為阿魏酸(ferulic acid)。
化合物4:黃色固體(乙酸乙酯);mp 372 ℃;EI-MSm/z178 [M]+;1H-NMR (CDCl3,400 MHz)δ:9.65 (1H,d,J=7.7 Hz,CHO),7.40 (1H,d,J=15.8 Hz,H-7),7.13 (1H,dd,J=8.2,1.9 Hz,H-5),7.07 (1H,d,J=1.9 Hz,H-3),6.96 (1H,d,J=8.2 Hz,H-6),6.60 (1H,dd,J=15.8,7.7 Hz,H-8),5.97 (1H,s,OH),3.95 (3H,s,OCH3);13C-NMR (CDCl3,100 MHz)δ:196.4 (C-9),156.1 (C-7),150.9 (C-1),149.8 (C-2),127.2 (C-8),127.0 (C-4),125.1 (C-5),116.8 (C-6),111.5 (C-3),56.1 (OCH3)。NMR數(shù)據(jù)與文獻報道一致[24],故鑒定化合物4為松柏醛(coniferyl aldehyde)。
化合物5:無色針晶(乙酸乙酯);mp 150 ℃;EI-MSm/z216 [M]+;1H-NMR (CDCl3,400 MHz)δ:7.77 (1H,d,J=9.6 Hz,H-4),7.69 (1H,d,J=2.2 Hz,H-2′),7.35 (1H,s,H-5),6.82(1H,d,J=2.2 Hz,H-3′),6.38 (1H,d,J=9.6 Hz,H-3),4.30 (3H,s,8-OCH3);13C-NMR (CDCl3,100 MHz)δ:160.6 (C-2),147.9 (C-7),146.8 (C-2′),144.4 (C-4),143.2 (C-8a),133.0 (C-8),126.3 (C-6),116.7 (C-4a),115.0 (C-3),113.0 (C-5),106.9 (C-3′),61.5 (8-OCH3)。NMR數(shù)據(jù)與文獻報道一致[25],故鑒定化合物5為花椒毒素(xanthotoxin)。
化合物6:無色針晶(乙酸乙酯);mp 276 ℃;EI-MSm/z202 [M]+;1H-NMR (400 MHz,DMSO-d6)δ:11.31 (1H,s,5-OH),8.26 (1H,d,J=9.8 Hz,H-4),7.91 (1H,d,J=2.3 Hz,H-2′),7.20 (1H,d,J=2.3 Hz,H-3′),7.16 (1H,s,H-8),6.27 (1H,d,J=9.8 Hz,H-3)。NMR數(shù)據(jù)與文獻報道一致[26],故鑒定化合物6為佛手酚(bergaptol)。
化合物7:淡黃色油狀物;EI-MSm/z260 [M]+;1H-NMR (CDCl3,400 MHz)δ:5.89 (1H,ddd,J=17.0,10.1,5.4 Hz,H-2),5.58~5.54 (1H,m,H-10),5.48 (1H,d,J=8.2 Hz,H-9),5.41 (1H,d,J=17.1 Hz,Hb-1),5.20 (1H,d,J=10.1 Hz,Ha-1),5.15 (1H,d,J=8.2 Hz,H-8),4.89 (1H,d,J=5.4 Hz,H-3),2.05 (2H,q,J=7.4 Hz,H-11),1.30~1.39 (m,2H),1.20~1.30 (m,8H),0.84 (3H,t,J=6.8 Hz,H-17);13C-NMR (CDCl3,100 MHz)δ:135.9 (C-2),134.2 (C-10),127.8 (C-9),117.2 (C-1),79.8 (C-4),78.4 (C-7),70.2 (C-5),68.7 (C-6),63.2 (C-3),58.4 (C-8),31.8 (C-15),29.3 (C-12),29.2 (C-13),29.1 (C-14),27.7 (C-11),22.6 (C-16),14.1 (C-17)。NMR數(shù)據(jù)與文獻報道一致[27],故鑒定化合物7為鐮葉芹二醇(falcarindiol)。
化合物8:無色油狀物;EI-MSm/z224[M]+;1H-NMR (CDCl3,400 MHz)δ:5.27 (1H,t,J=7.7 Hz,H-8),4.57 (1H,brs,H-7),3.95 (1H,brs,H-6),2.61 (1H,m,Hb-4),2.40 (1H,m,Ha-4),2.33 (2H,m,H-9),2.04 (1H,brs,Hb-5),1.83 (1H,brs,Ha-5),1.46 (2H,sext,H-10),0.92 (3H,t,J=7.2 Hz,H-11);13C-NMR (CDCl3,100 MHz)δ:169.5 (C-1),153.8(C-3),148.3 (C-3a),125.9 (C-7a),114.5 (C-8),68.2 (C-6),62.8 (C-7),28.2 (C-9),25.3 (C-5),22.3 (C-10),19.1 (C-4),13.9 (C-11)。NMR數(shù)據(jù)與文獻報道一致[28],故鑒定化合物8為洋川芎內(nèi)酯 H (senkyunolide H)。
化合物9:淡黃色油狀物;EI-MSm/z224[M]+;1H-NMR (CDCl3,400 MHz)δ:0.94 (3H,t,J=7.4 Hz,H-11),1.51 (2H,m,H-10),1.91 (1H,m,H-5),2.10 (H,m,H-5),2.31 (2H,q,H-9),2.39 (2H,m,H-4),3.98 (1H,m,H-6),4.48 (1H,d,J=5.2 Hz,H-7),5.27 (1H,t,J=8.4 Hz,H-8);13C-NMR (CDCl3,100 MHz)δ:169.3 (C-1),151.9 (C-3),151.1 (C-3a),125.8 (C-7a),115.5 (C-8),71.1 (C-6),67.6 (C-7),28.0 (C-9),26.8 (C-5),22.1 (C-10),19.6 (C-4),13.8 (C-11)。NMR數(shù)據(jù)與文獻報道一致[28],故鑒定化合物9為洋川芎內(nèi)酯I (senkyunolide I)。
化合物10:淡黃色油狀物;EI-MSm/z222[M]+;1H-NMR (CDCl3,400 MHz)δ:6.26 (1H,d,J=9.4 Hz,H-7),6.09 (1H,m,H-6),5.34 (1H,s,OH),2.67 (2H,m,H-9),2.27 (2H,m,H-6),2.48 (1H,m,H-5),2.23 (1H,m,H-5),1.65 (2H,m,H-10),0.92 (3H,t,J=7.3 Hz,H-11);13C-NMR (CDCl3,100 MHz)δ:202.7 (C-9),168.7 (C-1),155.1 (3a),131.8 (C-6),129.07,116.3 (C-7),102.8 (C-3),36.6 (C-9),22.6 (C-6),19.1 (C-4),17.1 (C-10),13.6 (C-11)。NMR數(shù)據(jù)與文獻報道一致[29],故鑒定化合物10為洋川芎內(nèi)酯D (senkyunolide D)。
化合物11:白色結(jié)晶(甲醇);mp 190 ℃;ESI-MSm/z207.1 [M+H]+;1H-NMR (CDCl3,400 MHz)δ:7.48 (1H,d,J=7.6 Hz,H-5),7.37 (1H,t,J=7.6 Hz,H-6),7.01 (1H,d,J=7.6 Hz,H-7),5.68 (1H,s,7-OH),5.56 (1H,dd,J=7.9,2.9 Hz,H-3),2.30 (1H,m,H-8),1.78 (1H,m,H-8),1.48~1.28 (4H,m,H-9,10),0.90 (3H,t,J=6.5 Hz,H-11);13C-NMR(CDCl3,100 MHz)δ:171.4 (C-1),136.4 (C-3a),152.5 (C-4),120.2 (C-5),130.4 (C-6),115.9 (C-7),127.9 (C-7a),80.9 (C-3),32.7 (C-8),27.0 (C-9),22.9 (C-10),14.0 (C-11)。NMR數(shù)據(jù)與文獻報道一致[30],故鑒定化合物11為4-羥基-3-丁基苯酞(4-hydroxy-3-butyl-phthalide)。
化合物12:無色油狀物;EI-MSm/z192 [M]+;1H-NMR (CDCl3,400 MHz)δ:6.20 (1H,d,J=9.7 Hz,H-7),5.95~5.86 (1H,m,H-6),4.92 (1H,dd,J=7.3,3.5 Hz,H-3),2.55~2.39 (2H,m,H-4),2.55~2.39 (2H,m,H-5),1.87 (1H,m,H-8),1.59~1.46 (1H,m,H-8),1.47~1.31 (2H,m,H-9),1.47~1.31 (2H,m,H-10),0.90 (3H,t,J=7.0 Hz,H-11);13C-NMR (CDCl3,100 MHz)δ:171.4 (C-1),161.5 (C-3a),128.4 (C-6),124.7 (C-7a),117.0 (C-7),82.6 (C-3),32.1 (C-8),26.9 (C-9),22.6 (C-5),22.4 (C-10),20.9 (C-4),14.0 (C-11)。NMR數(shù)據(jù)與文獻報道一致[31],故鑒定化合物12為洋川芎內(nèi)酯A(senkyunolide A)。
化合物13:淡黃色油狀物;EI-MSm/z190 [M]+;1H-NMR (CDCl3,400 MHz)δ:6.25 (1H,dt,J=9.7 1.5 Hz,H-7),5.95 (1H,m,H-6),5.18 (1H,t,J=8.0 Hz,H-8),2.57 (2H,t,J=13.5 Hz,H-5),2.55~2.39 (2H,m,H-4),2.33 (2H,m,H-9),1.47~1.31 (2H,m,H-10),0.92 (3H,t,J=7.5 Hz,H-11);13C-NMR (CDCl3,100 MHz)δ:167.4 (C-1),148.5 (C-3a),147.4 (C-3),129.7 (C-6),123.7 (C-7a),117.0 (C-7),112.1 (C-8),28.2 (C-9),22.4 (C-10),22.1 (C-5),18.9 (C-4),14.0 (C-11)。NMR數(shù)據(jù)與文獻報道一致[32],故鑒定化合物13為Z-藁本內(nèi)酯(Z-ligustilide)。
化合物14:淡黃色油狀物;ESI-MSm/z189 [M+H]+;1H-NMR (CDCl3,400 MHz)δ:6.13 (1H,d,J=8.1 Hz,H-7),6.00 (1H,m,H-6),5.10 (1H,t,J=7.6 Hz,H-8),2.60 (2H,m,H-9),2.54 (2H,m,H-5),2.39 (2H,m,H-4),1.40 (2H,m,H-10),0.96 (3H,t,J=7.2 Hz,H-11)。NMR數(shù)據(jù)與文獻報道一致[33],故鑒定化合物14為3-丁烯基苯酞(3-butylidenephthalide)。
化合物15:無色油狀物;EI-MSm/z194 [M]+;1H-NMR (CDCl3,400 MHz)δ:6.74 (1H,dt,J=3.2,3.2 Hz,H-7),3.94 (1H,ddd,J=8.8,7.2,5.6 Hz,H-3),2.53~2.41 (1H,m,H-3a),2.32 (1H,m,H-6),2.24~2.11 (1H,m,H-6),2.08~2.00 (1H,m,H-4),1.91 (1H,dddd,J=13.9,6.8,3.3,3.1 Hz,H-5),1.82~1.65 (2H,m,H-8),1.60~1.44 (2H,m,H-5,9),1.44~1.26 (2H,m,H-9,10),1.24~1.08 (1H,m,H-4),0.89 (3H,t,J=7.1 Hz,H-11);13C-NMR (CDCl3,100 MHz)δ:170.2 (C-1),135.2 (C-7),131.2 (C-7a),85.4 (C-3),43.1 (C-3a),34.4 (C-8),27.6 (C-9),25.4 (C-4),25.0 (C-6),22.6 (C-10),20.8 (C-5),13.9 (C-11)。NMR數(shù)據(jù)與文獻報道一致[34],故鑒定化合物15為新蛇床內(nèi)酯(neocnidilide)。
化合物16:白色固體(丙酮);mp 114 ℃;ESI-MSm/z381.2 [M+H]+;1H-NMR (CDCl3,400 MHz)δ:7.33 (1H,d,J=6.6 Hz,H-7′),5.05 (1H,t,J=7.9 Hz,H-8),4.97 (1H,t,J=7.4 Hz,H-8′),3.23 (1H,d,J=8.9 Hz,H-7),2.97 (1H,m,H-6′),2.53 (1H,t,J=7.9 Hz,H-6),2.26 (2H,m,H-9),2.19~2.11 (2H,m,H-9′),0.91 (3H,t,J=7.3,H-11),0.90 (3H,t,J=7.3,H-11′);13C-NMR (CDCl3,100 MHz)δ:168.5 (C-1),165.0 (C-1′),155.1 (C-3a),150.6 (C-3′),148.1 (C-3),142.2 (C-7′),134.2 (C-7′a),126.6 (C-7a),112.1 (C-8),108.6 (C-8′),47.7 (C-3′a),41.6 (C-7),41.6 (C-6′),38.4 (C-6),31.1 (C-4′),29.8 (C-3),28.1 (C-9),27.5 (C-9′),25.8 (C-5′),22.5 (C-10),22.4 (C-10′),19.8 (C-4),14.0 (C-11),13.9 (C-11′)。NMR數(shù)據(jù)與文獻報道一致[33],故鑒定化合物16為歐當(dāng)歸內(nèi)酯A (levistolide A)。
化合物17:白色粉末(甲醇),與對照品β-谷甾醇TLC分析,3種展開劑展開,色譜行為一致,故鑒定為β-谷甾醇(β-sitosterol)。
化合物18:黃色粉末(乙酸乙酯);mp 152 ℃;EI-MSm/z246 [M]+;1H-NMR (CDCl3,400 MHz)δ:8.12 (1H,d,J=9.8 Hz,H-4),7.62 (1H,d,J=2.2 Hz,H-2′),6.99 (1H,d,J=2.2 Hz,H-3′),6.29 (1H,d,J=9.8 Hz,H-3),4.17 (3H,s,OCH3),4.17 (3H,s,OCH3);13C-NMR (CDCl3,100 MHz)δ:60.9 (5-OCH3),61.7 (8-OCH3),105.1 (C-3′),107.7 (C-10),113.0 (C-3),114.9 (C-6),128.3 (C-8),139.4 (C-4),143.7 (C-9),144.3 (C-5),145.1 (C-2′),150.0 (C-7),160.4 (C-2)。NMR波譜數(shù)據(jù)與文獻報道一致[25],故鑒定化合物18為異茴芹內(nèi)酯(isopimpinellin)。
化合物19:無色油狀物;EI-MSm/z278 [M]+;1H-NMR (400 MHz,CDCl3)δ:7.72 (2H,dd,J=5.3,3.5 Hz,H-3,6),7.53 (2H,dd,5.3,3.5 Hz,H-4,5),4.30 (4H,t,J=6.7 Hz,H-9,9′),1.72 (4H,m,H-11,11′),1.44 (4H,m,H-10,10′),0.96 (6H,t,J=7.4 Hz,12,12′-CH3,)。NMR數(shù)據(jù)與文獻報道一致[35],故鑒定化合物19為鄰苯二甲酸正丁酯(dibutyl-O-phthalate)。
化合物20:無色油狀物;EI-MSm/z278 [M]+;1H-NMR (400 MHz,CDCl3)δ:7.72 (2H,dd,J=5.3,3.5 Hz,H-3,6),7.53 (2H,dd,J=5.5,3.5 Hz,H-4,5),4.09 (4H,d,J=6.7 Hz,H-1′,1″),2.04 (2H,m,H-2′,2″),0.99 (12H,d,J=6.7 Hz,H-3′,3″,4′,4″)。NMR數(shù)據(jù)與文獻報道一致[35],故鑒定化合物20為鄰苯二甲酸異丁酯(diisobutyl phthalate)。
化合物21:淡黃色油狀物;ESI-MSm/z379.1 [M+H]+;1H-NMR (400 MHz,CDCl3)δ:7.76 (1H,d,J=7.6 Hz,H-7),7.57 (1H,d,J=7.0 Hz,H-7′),7.53 (1H,t,J=7.7 Hz,H-5),7.41 (1H,t,J=7.7 Hz,H-6),7.15 (1H,d,J=7.7 Hz,H-4),3.70 (3H,s,OCH3),2.90 (1H,m,H-6′),2.62 (1H,m,H-4′),2.44 (2H,m,H-8′),2.13 (1H,m,H-5′),1.83 (1H,m,H-8),1.75 (1H,m,H-4′),1.53 (1H,m,H-5′),1.50 (2H,m,H-9),1.23 (2H,m,H-9′),1.13 (2H,m,H-10′),0.83 (3H,J=7.2 Hz,H-11′),0.76 (3H,t,J=7.2 Hz,H-11);13C-NMR (100 MHz,CDCl3)δ:207.1 (C-3′),170.4 (C-1),165.4 (C-1′),155.0 (C-3a),148.6 (C-7′),136.2 (C-7a′),133.9 (C-5),128.5 (C-6),125.7 (C-7a),124.6 (C-7),122.0 (C-4),89.0 (C-3),58.2 (C-3a′),52.1 (OCH3),49.1 (C-8),40.9 (C-8′),33.8 (C-6′),28.1 (C-9),26.3 (C-9),25.6 (C-9′),22.1 (C-10′),20.7 (C-10),17.9 (C-5′),14.0 (C-11),13.8 (C-11′)。NMR數(shù)據(jù)與文獻報道一致[36],故鑒定化合物21為川芎二內(nèi)酯R1(chuanxiongdiolide R1)。
化合物22:白色粉末(甲醇);mp 120~123 ℃;ESI-MSm/z230.2 [M+H]+。1H-NMR (400 MHz,CDCl3),δ:7.50 (1H,s,N-H),4.63 (1H,brs,Ha-15),4.89 (1H,brs,Hb-15),5.45 (1H,s,H-9),2.63 (1H,dd,J=3.8,16.4 Hz,Hb-6),2.46 (1H,d,J=13.4 Hz,Ha-6),2.36 (1H,m,H-3),2.34 (1H,m,H-1),2.04 (1H,m,H-1),1.64 (2H,m,H-2),1.61 (1H,m,H-3),1.58 (1H,m,H-5),1.87 (3H,s,H-13),0.91 (3H,s,H-14);13C-NMR (CDCl3,100 MHz)δ:173.3 (C-12),148.8 (C-4),141.8 (C-8),135.4 (C-7),124.9 (C-11),120.9 (C-9),107.2 (C-15),49.2 (C-5),39.5 (C-1),38.2 (C-10),36.4 (C-3),23.3 (C-6),22.5 (C-2),18.7 (C-14),8.3 (C-13)。NMR 數(shù)據(jù)與文獻報道一致[37],故鑒定化合物22為白術(shù)內(nèi)酰胺(atractylenolactam)。
化合物23:淡黃色結(jié)晶(甲醇);mp 188 ℃;EI-MSm/z216 [M]+;1H-NMR (CDCl3,400 MHz)δ:8.13 (1H,d,J=9.8 Hz,H-4),7.59 (1H,d,J=2.2 Hz,H-2′),7.10 (1H,s,H-8),7.02 (1H,d,J=2.2 Hz,H-3′),6.25 (1H,d,J=9.8 Hz,H-3),4.27 (3H,s,5-OCH3);13C-NMR (CDCl3,100 MHz)δ:161.2 (C-2),158.3 (C-7),152.7 (C-8a),149.5 (C-5),144.7 (C-2′),139.2 (C-4),112.7 (C-6),112.5 (C-3),106.4 (C-4a),105.0 (C-3′),93.8 (C-8),60.1 (5-OCH3)。NMR數(shù)據(jù)與文獻報道一致[38],故鑒定化合物23為香柑內(nèi)酯(bergapten)。
化合物24:黃色固體;mp 186 ℃;EI-MSm/z186 [M]+;1H-NMR (CDCl3,400 MHz)δ:7.80 (1H,d,J=9.6 Hz,H-4),7.69 (1H,d,J=2.2 Hz,H-2′),7.68 (1H,s,H-5),7.47 (1H,s,H-8),6.83 (1H,d,J=2.2 Hz,H-3′),6.38 (1H,d,J=9.6 Hz,H-3)。NMR數(shù)據(jù)與文獻報道一致[25],故鑒定化合物24為補骨脂素(psoralen)。
化合物25:白色粉末(丙酮);mp 146 ℃;EI-MSm/z286 [M]+;1H-NMR (CDCl3,400 MHz)δ:8.32 (1H,d,J=9.8 Hz,H-4),7.61 (1H,d,J=2.4 Hz,H-2′),7.17 (1H,s,H-8),6.84 (1H,d,J=2.4 Hz,H-3′),6.32 (1H,d,J=9.8 Hz,H-3),5.10 (2H,s,H-1″),2.86 (1H,q,J=8.0 Hz,H-3″),1.18 (6H,d,J=6.9 Hz,3″-CH3);13C-NMR (CDCl3,100 MHz)δ:208.9 (C-2″),161.1 (C-2),158.1 (C-7),152.7 (C-8a),148.0 (C-5),145.6 (C-2′),139.4 (C-4),113.7 (C-6),113.4 (C-3),107.6 (C-4a),104.2 (C-3′),95.2 (C-8),75.1 (C-1″),37.5 (C-3″),18.1 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[25],故鑒定化合物25為異氧化前胡內(nèi)酯(isooxypeucedanin)。
化合物26:淡黃色固體(乙酸乙酯);mp 102 ℃;EI-MSm/z300 [M]+;1H-NMR (CDCl3,400 MHz)δ:8.11 (1H,d,J=9.8 Hz,H-4),7.60 (1H,d,J=2.3 Hz,H-2′),6.99 (1H,J=2.3 Hz,H-3′),6.26 (1H,d,J=9.8 Hz,H-3),5.59 (1H,t,J=7.2 Hz,H-2″),4.83 (2H,d,J=7.2 Hz,H-1″),4.16 (3H,s,5-OCH3),1.72 (3H,s,3″-CH3),1.68 (3H,s,3″-CH3);13C-NMR (CDCl3,100 MHz)δ:160.7 (C-2),150.9 (C-7),145.2 (C-2′),144.5 (C-8a),144.4 (C-5),139.8 (C-3″),139.6 (C-4),126.9 (C-8),119.9 (C-2″),114.6 (C-6),112.8 (C-3),107.6 (C-4a),105.2 (C-3′),70.5 (C-1″),60.8 (5-OCH3),25.9 (3″-CH3),18.2 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[25],故鑒定化合物26為珊瑚菜內(nèi)酯(phellopterin)。
化合物27:白色粉末(乙酸乙酯);mp 130 ℃;EI-MSm/z304 [M]+;1H-NMR (CDCl3,400 MHz)δ:7.74 (1H,d,J=9.6 Hz,H-4),7.69 (1H,d,J=2.2 Hz,H-2′),7.35 (1H,s,H-5),6.81 (1H,d,J=2.2 Hz,H-3′),6.34 (1H,d,J=9.6 Hz,H-3),4.73 (1H,dd,J=10.2,2.7 Hz,Hb-1″),4.40 (1H,dd,J=10.2,7.9 Hz,Ha-1″),3.87 (1H,dd,J=7.9,2.7 Hz,H-2″),1.32 (3H,s,3″-CH3),1.28 (3H,s,3″-CH3);13C-NMR (CDCl3,100 MHz)δ:160.4 (C-2),148.0 (C-7),146.9 (C-2′),144.5 (C-4),143.3 (C-8a),131.7 (C-8),126.2 (C-6),116.5 (C-4a),114.8 (C-3),113.8 (C-5),106.9 (C-3′),76.1 (C-2″),75.7 (C-1″),71.7 (C-3″),25.2 (3″-CH3),26.7 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[38],故鑒定化合物27為獨活屬醇(heraclenol)。
化合物28:無色針晶 (石油醚-乙酸乙酯);mp 133 ℃;ESI-MSm/z287.1[M+H]+;1H-NMR (CDCl3,400 MHz)δ:7.76 (1H,d,J=9.6 Hz,H-4),7.66 (1H,d,J=2.0 Hz,H-2′),7.36 (1H,s,H-5),6.81 (1H,d,J=2.0 Hz,H-3′),6.37 (1H,d,J=9.6 Hz,H-3),5.19 (2H,s,H-1″),3.05 (1H,m,H-3″),1.21 (3H,s,3″-CH3),1.20 (3H,s,3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[39],故鑒定化合物28為牧草栓翅芹酮(pabularinone)。
化合物29:白色粉末(甲醇);mp 106 ℃;ESI-MSm/z317.1[M+H]+;1H-NMR (CDCl3,400 MHz)δ:8.08 (1H,d,J=9.8 Hz,H-4),7.59 (1H,d,J=2.3 Hz,H-2′),6.98 (1H,d,J=2.3 Hz,H-3′),6.23 (1H,d,J=9.8 Hz,H-3),5.00 (2H,s,H-1″),4.15 (3H,s,5-OCH3),3.07 (1H,q,J=6.9 Hz,H-3″),1.18 (6H,d,J=6.9 Hz,3″-CH3);13C-NMR (CDCl3,100 MHz)δ:210.3 (C-2″),160.2 (C-2),149.5 (C-7),145.3 (C-2′),144.7 (C-5),143.3 (C-8a),139.5 (C-4),126.4 (C-8),114.7 (C-6),112.8 (C-3),107.5 (C-4a),105.3 (C-3′),75.9 (C-1″),60.8 (5-OCH3),37.0 (C-3″),18.0 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[25],故鑒定化合物29為異白當(dāng)歸腦(anhydrobyakangelicin)。
化合物30:無色針晶(乙酸乙酯);mp 102 ℃;ESI-MSm/z271.1[M+H]+;1H-NMR (400 MHz,CDCl3)δ:7.76 (1H,d,J=9.6 Hz,H-4),7.68 (1H,d,J=2.2 Hz,H-2′),7.35 (1H,s,H-5),6.80 (1H,d,J=2.2 Hz,H-3′),6.35 (1H,d,J=9.6 Hz,H-3),5.60 (1H,t,J=7.2 Hz,H-2″),4.99 (2H,d,J=7.2 Hz,H-1″),1.73 (3H,s,3″-CH3),1.71 (3H,s,3″-CH3);13C-NMR (100 MHz,CDCl3)δ:160.7 (C-2),148.7 (C-7),146.8 (C-2′),144.5 (C-4),143.9 (C-8a),139.9 (C-3″),131.8 (C-8),126.0 (C-6),119.9 (C-2″),116.6 (C-4a),114.8 (C-3),113.3 (C-5),106.8 (C-3′),70.3 (C-1″),25.9 (3″-CH3),18.2 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[38],故鑒定化合物30為歐前胡素(imperatorin)。
化合物31:無色針晶(乙酸乙酯);mp 108 ℃;ESI-MSm/z271.1[M+H]+;1H-NMR (400 MHz,CDCl3)δ:8.16 (1H,d,J=9.8 Hz,H-4),7.59 (1H,d,J=2.4 Hz,H-2′),7.15 (1H,s,H-8),6.95 (1H,d,J=2.4 Hz,H-3′),6.27 (1H,d,J=9.8 Hz,H-3),5.54 (1H,t,J=7.0 Hz,H-2″),4.92 (2H,d,J=7.0 Hz,H-1″),1.80 (3H,s,3″-CH3),1.70 (3H,s,3″-CH3);13C-NMR (100 MHz,CDCl3)δ:161.4 (C-2),158.3 (C-7),152.8 (C-9),149.1 (C-5),145.0 (C-2′),140.0 (C-3″),139.7 (C-4),119.3 (C-2″),114.4 (C-6),112.7 (C-3),107.7 (C-4a),105.2 (C-3′),94.4 (C-8),69.9 (C-1″),25.9 (3″-CH3),18.4 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[38],故鑒定化合物31為異歐前胡素(isoimperatorin)。
化合物32:無色針晶 (甲醇);mp 178 ℃;ESI-MSm/z271.5 [M+H]+;1H-NMR (DMSO-d6,400 MHz)δ:8.18 (1H,d,J=9.8 Hz,H-4),8.04 (1H,br s,H-2′),7.08 (1H,br s,H-3′),6.40 (1H,d,J=9.8 Hz,H-3),5.12 (1H,t,J=6.6 Hz,H-2″),3.72 (2H,d,J=6.6 Hz,H-1″),3.19 (1H,br s,5-OH),1.80 (3H,s,3″-CH3),1.63 (3H,s,3″-CH3);13C-NMR (DMSO-d6,100 MHz)δ:160.2 (C-2),146.9 (C-2′),145.4 (C-7),142.0 (C-5,9),140.9 (C-4),131.2 (C-3″),128.1 (C-6),124.9 (C-8),123.2 (C-2″),113.9 (C-10),113.6 (C-3),106.6 (C-3′),27.4 (3″-CH3),25.1 (C-1″),18.0 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[40],故鑒定化合物32為別異歐前胡素(alloisoimperatorin)。
化合物33:淡黃色固體(丙酮);mp 138 ℃;EI-MSm/z304 [M]+;1H-NMR (400 MHz,CDCl3)δ:8.16 (1H,d,J=9.8 Hz,H-4),7.59 (1H,d,J=1.8 Hz,H-2′),7.11 (1H,s,H-8),6.98 (1H,d,J=1.8 Hz,H-3′),6.24 (1H,d,J=9.8 Hz,H-3),4.54 (1H,dd,J=9.7,2.5 Hz,Hb-1″),4.43 (1H,t,J=9.7 Hz,Ha-1″),3.91 (1H,d,J=7.2 Hz,H-2″),1.36 (3H,s,3″-CH3),1.31 (3H,s,3″-CH3);13C-NMR (100 MHz,CDCl3)δ:161.3 (C-2),158.2 (C-7),152.6 (C-8a),148.7 (C-5),145.4 (C-2′),139.3 (C-4),114.3 (C-6),113.1 (C-3),107.4 (C-4a),104.9 (C-3′),94.8 (C-8),76.7 (C-3″),74.6 (C-2″),71.8 (C-1″),26.8 (3″-CH3),25.3 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[38],故鑒定化合物33為水合氧化前胡內(nèi)酯 (oxypeucedanin hydrate)。
化合物34:白色粉末(甲醇);mp 118 ℃;ESI-MSm/z357.1 [M+Na]+;1H-NMR (400 MHz,CDCl3)δ:8.12 (1H,d,J=9.8 Hz,H-4),7.63 (1H,d,J=2.3 Hz,H-2′),7.02 (1H,d,J=2.3 Hz,H-3′),6.29 (1H,d,J=9.8 Hz,H-3),4.60 (1H,dd,J=10.2,2.6 Hz,Hb-1″),4.26 (1H,dd,J=10.2,7.9 Hz,Ha-1″),4.19 (3H,s,5-OCH3),3.83 (1H,dd,J=7.9,2.6 Hz,H-2″),1.32 (3H,s,3″-CH3),1.28 (3H,s,3″-CH3);13C-NMR (100 MHz,CDCl3)δ:160.3 (C-2),150.3 (C-7),145.4 (C-2′),145.0 (C-5),144.1 (C-8a),139.6 (C-4),126.9 (C-8),114.7 (C-6),113.0 (C-3),107.7 (C-4a),105.5 (C-3′),76.2 (C-2″),76.1 (C-1″),71.7 (C-3″),60.9 (5-OCH3),26.8 (3″-CH3),25.2 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[25],故鑒定化合物34為白當(dāng)歸素(byakangelicin)。
化合物35:白色粉末(乙酸乙酯);mp 260 ℃;ESI-MSm/z431 [M+Na]+,407 [M-H]-;1H-NMR (DMSO-d6,400 MHz)δ:7.95 (1H,d,J=9.5 Hz,H-4),7.48 (1H,s,H-5),6.82 (1H,s,H-8),6.22 (1H,d,J=9.5 Hz,H-3),4.82~4.89 (4H,m,H-2′,4″-OH,3″-OH,2″-OH),4.40 (1H,d,J=7.8 Hz,H-1″),4.30 (1H,t,J=5.7 Hz,6″-OH),3.44~3.33 (2H,m,Hb-6″,Ha-6″),3.33~3.03 (5H,m,H-3′,3″,4″,5″),2.88~2.83 (1H,m,H-2″),1.26 (3H,s,4′-CH3),1.23 (3H,s,4′-CH3);13C-NMR (DMSO-d6,100 MHz)δ:163.2 (C-7),160.6 (C-2),155.1 (C-9),144.8 (C-4),125.7 (C-6),124.0 (C-5),112.3 (C-10),111.4 (C-3),97.4 (C-1″),96.9 (C-8),90.2 (C-2′),77.0 (C-4′),77.0 (C-5″),76.6 (C-3″),73.6 (C-2″),70.1 (C-4″),61.0 (C-6″),28.9 (C-3′),23.2 (4′-CH3),21.9 (4′-CH3)。NMR數(shù)據(jù)與文獻報道一致[40],故鑒定化合物35為印枳苷[(-)-marmesinin]。
化合物36:白色針狀結(jié)晶(甲醇);mp 258 ℃;ESI-MSm/z447 [M+Na]+;1H-NMR (DMSO-d6,400 MHz)δ:8.00 (1H,d,J=9.6 Hz,H-4),7.66(1H,s,H-5),6.96 (1H,s,H-8),6.28 (1H,d,J=9.6 Hz,H-3),5.20~5.27 (2H,m,H-3′,3′-OH),4.99 (1H,d,J=3.1 Hz,4″-OH),4.89 (1H,br s,3″-OH),4.86 (1H,br s,2″-OH),4.52~4.55 (2H,m,H-1″,H-2′),4.31 (1H,br s,6″-OH),3.36 (1H,overlap,Ha-6″,Hb-6″),3.15 (1H,m,H-5″),3.06 (2H,br s,H-3″,4″),2.88 (1H,d,J=7.2 Hz,H-2″),1.47 (6H,s,2×4′-CH3);13C-NMR (DMSO-d6,100 MHz)δ:162.4 (C-7),160.4 (C-2),156.1 (C-9),144.9 (C-4),128.6 (C-6),125.7 (C-5),112.9 (C-10),111.8 (C-3),97.7 (C-1″),97.3 (C-8),91.9 (C-2′),77.5 (C-3′),76.9 (C-3″),76.7 (C-5″),73.5 (C-2″),70.1 (C-4″),69.8 (C-4′),60.8 (C-6″),24.6 (4′-CH3),22.8 (4′-CH3)。NMR數(shù)據(jù)與文獻報道一致[41],故鑒定化合物36為(2′S,3′R)-3′-羥基印枳苷[(2′S,3′R)-3′-hydroxymarmesinin]。
化合物37:白色固體(乙腈-水);mp 925 ℃;ESI-MSm/z496 [M+H]+;1H-NMR (DMSO-d6,400 MHz)δ:8.18 (1H,d,J=9.8 Hz,H-4),8.10 (1H,d,J=2.3 Hz,H-2′),7.34 (1H,d,J=2.3 Hz,H-3′),6.34 (1H,d,J=9.8 Hz,H-3),5.25-4.93 (3H,br s,2?-OH,3?-OH,4?-OH),4.50-4.43 (4H,m,H-1?,Ha-1″,Hb-1″,3″-OH),4.18 (3H,s,5-OCH3),4.12 (1H,br s,6?-OH),3.73 (1H,t,J=4.9 Hz,H-2″),3.40 (2H,overlap,H-6?),3.19~3.08 (3H,m,H-3?,4?,5?),3.01 (1H,t,J=8.3 Hz,H-2?),1.26 (3H,s,3″-CH3),1.24 (3H,s,3″-CH3);13C-NMR(DMSO-d6,100 MHz)δ:159.9 (C-2),149.1 (C-7),146.6 (C-2′),144.3 (C-5),143.1 (C-9),139.8 (C-4),126.6 (C-8),114.8 (C-6),112.8 (C-3),107.1 (C-10),105.9 (C-3′),105.2 (C-1?),86.0 (C-2″),76.8 (C-5?),76.6 (C-3?),74.4 (C-1″),74.2 (C-2?),71.4 (C-3″),70.0 (C-4?),61.0 (C-6?),61.0 (5-OCH3),26.6 (3″-CH3),25.3 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[41],故鑒定化合物37為仲-O-β-D-吡喃葡萄糖基白當(dāng)歸素(sec-O-β-D-glucopyranosyl-byakangelicin)。
化合物38:白色固體(甲醇);mp 944 ℃;ESI-MSm/z519 [M+Na]+;1H-NMR (DMSO-d6,400 MHz)δ:8.16 (1H,d,J=9.6 Hz,H-4),8.10 (1H,d,J=2.2 Hz,H-2′),7.35 (1H,d,J=2.2 Hz,H-3′),6.35 (1H,d,J=9.6 Hz,H-3),4.86 (2H,br s,3?-OH,4?-OH),4.70 (1H,d,J=7.8 Hz,H-1?),4.66 (1H,dd,J=10.9,2.8 Hz,Ha-1″),4.37 (1H,d,J=10.9,6.2 Hz,Hb-1″),4.56 (1H,d,J=3.4 Hz,2?-OH),4.34 (1H,s,2″-OH),4.36 (1H,s,6?-OH),4.17 (3H,s,5-OCH3),3.94 (1H,dd,J=6.2,2.8 Hz,H-2″),3.69 (1H,dd,J=11.5,2.7 Hz,Ha-6?),3.44 (1H,m,Hb-6?),3.25~3.07 (3H,m,H-3?,4?,5?),3.01 (1H,m,H-2?),1.23 (3H,s,3″-CH3),1.11 (3H,3″-CH3);13C-NMR (DMSO-d6,100 MHz)δ:159.8 (C-2),149.7 (C-7),146.4 (C-2′),144.3 (C-5),143.2 (C-9),139.9 (C-4),126.3 (C-8),114.6 (C-6),112.7 (C-3),107.1 (C-10),105.9 (C-3′),102.0 (C-1?),82.9 (C-3″),76.9 (C-1″),76.7 (C-2″),75.3 (C-3?),75.6 (C-5?),73.9 (C-2?),70.2 (C-4?),61.6 (C-6?),60.7 (5-OCH3),27.4 (3″-CH3),25.5 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[41],故鑒定化合物38為叔-O-β-D-吡喃葡萄糖基白當(dāng)歸素(tert-O-β-D-glucopyranosyl-byakangelicin)。
化合物39:白色粉末(乙腈-水);mp 614 ℃;ESI-MSm/z425 [M+H]+。1H-NMR (400 MHz,DMSO-d6)δ:8.03 (1H,d,J=9.5 Hz,H-4),7.69 (1H,s,H-5),6.93 (1H,s,H-8),6.27 (1H,d,J=9.5 Hz,H-3),5.25 (1H,d,J=6.6 Hz,H-3′),5.24 (1H,s,3′-OH),5.01 (1H,s,2″-OH),4.93 (1H,s,3″-OH),4.88 (1H,s,4″-OH),4.53 (1H,d,J=7.1 Hz,H-1″),3.36 (2H,overlap,H-6),3.16 (1H,s,H-3″),3.06 (1H,m,H-4),3.05 (1H,m,H-5),2.88 (1H,m,H-2′),1.47 (6H,s,3″-CH3);13C-NMR (100 MHz,DMSO-d6)δ:162.2 (C-7),160.3 (C-2),156.0 (C-8a),144.8 (C-4),128.5 (C-6),125.6 (C-5),112.7 (C-4a),111.7 (C-3),97.6 (C-1″),97.2 (C-8),91.8 (C-2′),77.4 (C-3′),76.8 (C-3″),76.6 (C-5″),73.3 (C-2″),70.0 (C-4″),69.7 (C-3′),60.7 (C-6″),24.5 (3″-CH3),22.7 (3″-CH3)。NMR數(shù)據(jù)與文獻報道一致[42],故鑒定化合物39為(2′R,3′S)-3′-羥基紫花前胡苷[(2′R,3′S)-3′-hydroxynodakenin]。
化合物40:油狀物(丙酮);ESI-MSm/z387 [M+Na]+;1H-NMR (DMSO-d6,400 MHz)δ:8.15 (1H,d,J=9.6 Hz,H-4),8.11 (1H,d,J=2.2 Hz,H-2′),7.69 (1 H,s,H-5),7.09 (1H,d,J=2.2 Hz,H-3′),6.44 (1H,d,J=9.6 Hz,H-3),5.62 (1H,d,J=7.5 Hz,H-1″),5.53 (1H,d,J=5.0 Hz,4″-OH),5.15 (1H,d,J=3.6 Hz,3″-OH),5.03 (1H,br s,2″-OH),4.34 (1H,t,J=5.6 Hz,Ha-6″),3.53 (1H,dd,J=11.6,4.9 Hz,Hb-6′),3.39 (2H,overlap,H-3″,5″),3.21 (2H,br s,H-2″,4″);13C-NMR (DMSO-d6,100 MHz)δ:160.1 (C-2),148.0 (C-2′),146.3 (C-7),145.4 (C-4),142.3 (C-9),128.9 (C-8),126.1 (C-6),116.5 (C-10),114.4 (C-3),114.2 (C-5),107.1 (C-3′),102.1 (C-1″),77.7 (C-5″),76.9 (C-3″),74.1 (C-2″),69.8 (C-4″),60.7(C-6″)。NMR數(shù)據(jù)與文獻報道一致[41],故鑒定化合物40為花椒毒酚-8-O-β-D-吡喃葡萄糖苷(xanthotoxol-8-O-β-D-glucopyranoside)。
化合物41:白色粉末(乙腈-水);mp 236 ℃;ESI-MSm/z290 [M+Na]+。1H-NMR (DMSO-d6,400 MHz)δ:8.36 (1H,s,H-2),8.14 (1H,s,H-8),7.36 (2H,br s,-NH2),5.88 (1H,d,J=6.1 Hz,H-1′),5.47 (1H,d,J=5.7 Hz,2′-OH),5.44 (1H,m,3′-OH),5.21 (1H,d,J=3.8 Hz,4′-OH),4.64 (1H,q,J=5.5 Hz,H-2′),4.15 (1H,d,J=2.8 Hz,H-3′),3.97 (1H,d,J=2.6 Hz,H-4′),3.68 (1H,m,Ha-5′),3.56 (1H,m,Hb-5′);13C-NMR (DMSO-d6,100 MHz)δ:156.2 (C-6),152.4 (C-2),149.0 (C-4),139.9 (C-8),119.3 (C-5),87.9 (C-1′),73.4 (C-2′),70.6 (C-3′),85.9 (C-41′),61.7 (C-5′)。NMR數(shù)據(jù)與文獻報道一致[43],故鑒定化合物41為腺苷(adenosine)。
“都梁丸”為中藥復(fù)方中典型的藥對之一,組方精當(dāng)。前期工作中,我們首先對組方藥味中的白芷[25,38,40-41,44-49]和川芎[50-51]的化學(xué)成分進行了詳細研究,本文首次把“都梁丸”作為單味藥處理,對其物質(zhì)基礎(chǔ)進行了化學(xué)成分的研究,分離鑒定了41個化合物,明確了其中的香豆素及香豆素苷類化合物應(yīng)該來源于白芷,藁本內(nèi)酯類化合物應(yīng)該來源于川芎。由于“都梁丸”臨床療效確切,且組方簡單,易于采用現(xiàn)代化的分析檢測手段對該復(fù)方進行研究,從中找出規(guī)律,闡明物質(zhì)基礎(chǔ),研制出現(xiàn)代中藥。詳細的研究工作嗣后進行。
[1] 楊秀偉.中藥物質(zhì)基礎(chǔ)研究是中藥繼承、發(fā)展、創(chuàng)新的關(guān)鍵科學(xué)問題[J].中國中藥雜志,2015,40(17):3429-3434.
[2] 馬兆堂,楊秀偉.黃連解毒湯醋酸乙酯溶性化學(xué)成分的研究[J].中國中藥雜志,2008,33(18):2080-2086.
[3] 馬兆堂,楊秀偉,鐘國躍.黃連解毒湯中1個新的黃酮苷[J].中國中藥雜志,2009,34(9):1097-1100.
[4] Ma Z T,Yang X W,Zhang Y,et al.Pharmacochemistry and integrated pharmacokinetics of six alkaloids after oral administration of Huang-Lian-Jie-Du-Tang decoction[J].J Asian Nat Prod Res,2014,16(5):483-496.
[5] 王付榮,葛喜珍,楊秀偉.通脈方化學(xué)成分研究[J].中國實驗方劑學(xué)雜志,2011,17(20):61-69.
[6] Wang F R,Yang X W,Zhang Y,et al.Three new isoflavone glycosides from Tongmai granules[J].J Asian Nat Prod Res,2011,13(4):319-329.
[7] 王付榮,楊秀偉.HPLC法同時測定通脈方中6個異黃酮類成分的含量[J].藥物分析雜志,2011,31(9):1626-1630.
[8] 吳帥,徐嵬,楊秀偉.人源腸內(nèi)菌轉(zhuǎn)化通脈方的化學(xué)研究[J].中國中藥雜志,2013,38(20):3510-3519.
[9] Wu S,Xu W,Wang F R,et al.Study of the biotransformation of Tongmai Formula by human intestinal flora and its intestinal permeability across the Caco-2 cell monolayer[J].Molecules,2015,20(10):18704-18716.
[10]Qian P,Yang X W.New limonoids from Coptidis Rhizoma-Euodiae Fructus couple[J].J Asian Nat Prod Res,2014,16(4):333-344.
[11]Qian P,Yang X W.Five new alkaloids from Coptidis Rhizoma-Euodiae Fructus couple and their cytotoxic activities against gastrointestinal cancer cells[J].Fitoterapia,2014,93:74-80.
[12]錢平,楊秀偉.左金方的生物堿類成分及其對腫瘤細胞的細胞毒活性[J].中草藥,2014,25(1):8-15.
[13]Gao X,Yang X W,Marriott P J.Evaluation of Coptidis Rhizoma-Euodiae Fructus couple and Zuojin products based on HPLC fingerprint chromatogram and simultaneous determination of main bioactive constituents[J].Pharm Biol,2013,51(11):1384-1392.
[14]楊秀偉,肖詩鷹,楊智,等. 精制吳茱萸膠囊化學(xué)成分的研究[J].北京大學(xué)學(xué)報(醫(yī)學(xué)版),2001,33(3):280-282.
[15]Hu C Q,Yang X W.Simultaneous determination of seven alkaloids and two flavonoid glycosides in Wuzhuyu decoction by RP-HPLC-DAD[J].J Chin Pharm Sci,2012,21(4):338-344.
[16]Hu C Q,Li F,Yang X W.Simultaneous determination and pharmacokinetic analysis of seven alkaloids and two flavonoids from rat plasma by HPLC-DAD after oral administration of Wuzhuyu decoction[J].J Asian Nat Prod Res,2012,14(4):370-381.
[17]國家藥典委員會.中華人民共和國藥典:一部[S].北京:中國醫(yī)藥科技出版社,2015:1325.
[18]韓笑,徐祎,許建陽,等.都梁丸提取液的鎮(zhèn)痛作用及其對小鼠腦組織中5-HT、5-HIAA、DA及NE含量的影響[J].中國中西醫(yī)結(jié)合雜志,2004,24(S1):29-31.
[19]韓笑,許建陽,徐祎,等.都梁丸提取液鎮(zhèn)痛作用及其對血清中5-HTP、5-HIAA含量的影響[J].中國中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志,2003,9(12):41-42.
[20]韓笑,劉文,邱德文,等.都梁丸提取液鎮(zhèn)痛作用及對外周組織c-fos基因表達影響的實驗研究[J].中國實驗方劑學(xué)雜志,2003,9(4):34-36.
[21]王富乾,張錦文,姚廣民,等.烏桕葉化學(xué)成分研究[J].中國藥學(xué)雜志,2013,48(22):1908-1911.
[22]王峰,方振峰.安息香化學(xué)成分研究[J].中國實驗方劑學(xué)雜志,2012,18(17):89-92.
[23]鐘吉強,狄斌,馮鋒.黃花倒水蓮的化學(xué)成分[J].中草藥,2009,40(6):844-846.
[24]廖金華,胡旭佳,苑春茂,等.馬檳榔果實的化學(xué)成分研究[J].天然產(chǎn)物研究與開發(fā),2014,26(11):1780-1784.
[25]趙愛紅,楊秀偉.興安白芷脂溶性部位中新的天然產(chǎn)物[J].中草藥,2014,45(13):1820-1828.
[26]牛艷,王磊,黃曉君,等.化橘紅香豆素類的化學(xué)成分[J].暨南大學(xué)學(xué)報(自然科學(xué)與醫(yī)學(xué)版),2012,33(5):501-505,515.
[27]Lechner D,Stavri M,Oluwatuyi M,et al.The anti-staphylococcal activity ofAngelicadahurica(Bai Zhi)[J].Phytochemistry,2004,65(3):331-335.
[28]陳鴛誼,李行諾,張翠萍,等.當(dāng)歸中的一個新苯酞類化合物[J].浙江工業(yè)大學(xué)學(xué)報,2011,39(5):524-527.
[29]Kobayashi M,F(xiàn)ujita M,Mitsuhashi H.Components ofCnidiumofficinaleMakino:occurrence of pregnenolone,coniferyl ferulate,and hydroxyphthalides[J].Chem Pharm Bull,1984,32(9):3770-3773.
[30]郝淑娟,張振學(xué),田洋,等.川芎化學(xué)成分研究[J].中國現(xiàn)代中藥,2010,12(3):22-25,38.
[31]魏倩,楊建波,王愛國,等.茶芎地上部位化學(xué)成分研究[J].中草藥,2014,45(14):1980-1983.
[32]肖永慶,李麗,游小琳,等.川芎化學(xué)成分研究[J].中國中藥雜志,2002,27(7):42-45.
[33]Liu Q,Zhou J D,Yu J G,et al.Systematic and efficient separation of 11 compounds fromRhizomaChuanxiongvia counter-current chromatography-solid phase extraction-counter-current chromatography hyphenation[J].J Chromatogr A,2014,1364:204-213.
[34]Tsukamoto T,Ishikawa Y,Miyazawa M.Larvicidal and adulticidal activity of alkylphthalide derivatives from rhizome ofCnidiumofficinaleagainstDrosophilamelanogaster[J].J Agric Food Chem,2005,53(14):5549-5553.
[35]蘇麗麗,唐旭利,張婧,等.中國南海海底柏柳珊瑚化學(xué)成分研究[J].中國海洋藥物,2011,30(5):18-22.
[36]Huang J,Lu X Q,Zhang C,et al.Anti-inflammatory ligustilides fromLigusticumchuanxiongHort.[J].Fitoterapia,2013,91:21-27.
[37]Wang X C,Wu W Q,Ma S P,et al.A new sesquiterpenoid from the roots ofChloranthusfortunei[J].Chin J Nat Med,2008,6(6):404-407.
[38]趙愛紅,楊秀偉,楊鑫寶,等.祁白芷根中新的天然產(chǎn)物[J].中國中藥雜志,2012,37(16):2400-2407.
[39]肖永慶,崔淑蓮,劉曉宏,等.云南羌活化學(xué)成分研究(Ⅰ)[J].中國中藥雜志,1995,20(7):423-424,448.
[40]鄧改改,楊秀偉,張友波,等.川白芷根脂溶性化學(xué)成分研究[J].中國中藥雜志,2015,40(11):2148-2156.
[41]鄧改改,崔治家,楊秀偉.川白芷根極性化學(xué)成分研究[J].中國中藥雜志,2015,40(19):3805-3810.
[42]肖永慶,李麗,谷口雅顏,等.云南羌活的苷類成分[J].藥學(xué)學(xué)報,2001,36(7):519-522.
[43]游小琳,李麗,肖永慶.白芷水溶性部分化學(xué)成分研究[J].中國中藥雜志,2002,27(4):279-280.
[44]韋瑋,徐嵬,楊秀偉,等.杭白芷醋酸乙酯部位化學(xué)成分研究[J].中草藥,2016,47(15):2606-2613.
[45]Chen T L,Zhang Y B,Xu W,et al.Biotransformation of isoimperatorin by rat liver microsomes and its quantification by LC-MS/MS method[J].Fitoterapia,2014,93:88-97.
[46]Deng G G,Wei W,Yang X W,et al.New coumarins from the roots ofAngelicadahuricavar.formosana cv.Chuanbaizhi and their inhibition on NO production in LPS-activated RAW264.7 cells[J].Fitoterapia,2015,101:194-200.
[47]Wei W,Wu X W,Deng G G,et al.Anti-inflammatory coumarins with short-and long-chain hydrophobic groups from roots ofAngelicadahuricacv.Hangbaizhi[J].Phytochemistry,2016,123:58-68.
[48]趙愛紅,楊鑫寶,楊秀偉,等.興安白芷的揮發(fā)油成分分析[J].藥物分析雜志,2012,32(5):763-768.
[49]趙愛紅,楊秀偉,楊鑫寶,等.祁白芷揮發(fā)油成分的GC-MS分析[J].中國中藥雜志,2011,36(5):603-607.
[50]Wei W,Wu X W,Yang X W.Novel phthalide derivatives from the rhizomes ofLigusticumchuanxiongand their inhibitory effect against lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophage cells[J].RSC Adv,2016,66(6):61037-61046.
[51]吳琦,楊秀偉.國家中藥材GAP基地產(chǎn)川芎揮發(fā)油化學(xué)成分的GC-MS分析[J].中國中藥雜志,2008,33 (3):276-280.
ChemicalConstituentsfromCoupletMedicineof“Duliang”Pill
WEI Wei1,WANGLi2a,LIANGLi2a,WANGYuzhen2a,HAILina3,YANGXiuwei1*
(1.StateKeyLaboratoryofNaturalandBiomimeticDrugs,DepartmentofNaturalMedicines,SchoolofPharmaceuticalSciences,PekingUniversity,Beijing100191,China;2.ChangzhiMedicalCollege,Changzhi046000,China;3.BeijingZhendongGuangmingPharmaceuticalResearchInstituteCo.Ltd.,Beijing100120,China)
Objective:To study the chemical constituents of the couplet medicine of "Duliang" Pill.Methods:Repeated column chromatography on silica gel and HPLC were applied to the separation of compounds and their structures were determined by spectroscopic data analyses of MS and NMR.Results:Forty-one compounds were obtained and identified as 5-hydroxymethylfurfural (1),vanillin (2),ferulic acid (3),coniferyl aldehyde (4),xanthotoxin (5),bergaptol (6),falcarindiol (7),senkyunolide H (8),senkyunolide I (9),senkyunolide D (10),4-hydroxy-3-butyl-phthalide (11),senkyunolide A (12),Z-ligustilide (13),3-butylidenephthalide (14),neocnidilide (15),levistolide A (16),β-sitosterol (17),isopimpinellin (18),dibutyl-O-phthalate (19),diisobutyl phthalate (20),chuanxiongdiolide R1(21),atractylenolactam (22),bergapten (23),psoralen (24),isooxypeucedanin (25),phellopterin (26),heraclenol (27),pabularinone (28),anhydrobyakangelicin (29),imperatorin (30),isoimperatorin (31),alloisoimperatorin (32),oxypeucedanin hydrate (33),byakangelicin (34),(-)-marmesinin] (35),(2′S,3′R)-3′-hydroxymarmesinin (36),sec-O-β-D-glucopyranosylbyakangelicin (37),tert-O-β-D-glucopyranosylbyakangelicin (38),(2′R,3′S)-3′-hydroxynodakenin(39),xanthotoxol-8-O-β-D-glucopyranoside (40),and adenosine (41),respectively.Conclusion:Originally,coumarins and coumarin glycosides were from Angelicae Dahuricae Radix,and phthalides were from Chuanxiong Rhizoma.
The couplet medicine;Duliang Pill;Angelicae Dahuricae Radix;Chuanxiong Rhizoma;chemical constituents
國家自然科學(xué)基金項目(81473321)
] 楊秀偉,教授,博士生導(dǎo)師,研究方向:中藥有效物質(zhì)基礎(chǔ)和藥物代謝;Tel:(010)82801569,E-mail:xwyang@bjmu.edu.cn
10.13313/j.issn.1673-4890.2017.7.009
2016-11-13)
*[
a共同第二作者